copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Trimtech Therapeutics We are creating a differentiated portfolio of potent, highly specific degraders, known as TRIMTACs ® and TRIMGLUEs ®, that selectively target the removal of toxic proteins for the treatment of intractable CNS and inflammatory disorders
Engineered Solutions for Process Control • TrimTeck As a respected supplier to the U S government, Trimteck combines its engineering expertise and unparalleled customer service to offer high-quality, differentiated process control solutions conforming to the strictest military and international standards
TRIMTECH Therapeutics raises $31M seed funding to advance targeted . . . TRIMTECH is leveraging the innate properties of the E3 ubiquitin ligase TRIM21 to selectively and potently degrade protein aggregates associated with a range of diseases which are not well served by current TPD approaches
Trimtech closes $31m to advance CNS therapeutics pipeline Trimtech Therapeutics has closed a seed funding round of $31m (£25m) to advance its pipeline of the central nervous system (CNS)-penetrant therapeutics that are based on Trimtacs, the aggregate-selective degrader molecules
TRIMTECH Therapeutics - Cambridge Innovation Capital TRIMTECH Therapeutics is creating a differentiated portfolio of potent, highly specific degraders, known as TRIMTACs™ and TRIMGLUEs™, that selectively target the removal of toxic proteins for the treatment of intractable CNS and inflammatory disorder
Science - Trimtech Therapeutics At TRIMTECH we are developing a unique pipeline of aggregate selective protein degraders known as TRIMTACs™ and TRIMGLUEs™ for the treatment of severe neurodegenerative and inflammatory diseases